Clinical trials: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, open to volunteers
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT05755087
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lapo Alinari
DLBCL
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a multicenter, open-label phase Ib study, evaluating the safety, tolerability, preliminary efficacy and PK characteristics of Rocbrutinib (LP-168) combined with R-GemOx in patients with R/R non-GCB DLBCL.
- Trial name
- NCT07570017
- Testing
- Rocbrutinib, R-GemOx
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with…
- Trial name
- HyDEF (NCT06898905)
- Testing
- Bridging Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Trial name
- NCT04836507
- Testing
- CRC01, Fludarabine, Cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- Curocell Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with…
- Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Trial name
- Archonc-001 (NCT07476378)
- Testing
- MTM-H-001 Injection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined…
- Conditions
- Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03418038
- Testing
- Ascorbic Acid, Carboplatin, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
DLBCL - Diffuse Large B Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory…
- Trial name
- NCT07570823
- Testing
- SCTB35 injection, Rituxumab, Gemcitabine
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sinocelltech Ltd.
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R)…
- Trial name
- NCT06768905
- Testing
- Iomab-B, CAR-T cell
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to…
- Trial name
- NCT05800405
- Testing
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06649812
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 115 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma Refractory
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
This is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large…
- Trial name
- GLO-PACT (NCT07387848)
- Testing
- Glofitamab
- Where
- Lebanon
- Volunteers
- 40 people
- Sponsor
- American University of Beirut Medical Center
Diffuse Large B-Cell Lymphoma
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
- Trial name
- GlofitReal (NCT07200375)
- Testing
- Glofitamab
- Where
- 22 sites in China, Hong Kong
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Large B-cell Lymphoma, Hodgkin Lymphoma
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
- Trial name
- NCT07164469
- Testing
- Fludarabine, Cyclophosphamide, CD70.CAR NK Cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with…
- Conditions
- Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
- Trial name
- NCT06980116
- Testing
- EXS73565
- Where
- 17 sites in Georgia, Greece and 5 more
- Volunteers
- 85 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma.
- Trial name
- NCT07862764
- Volunteers
- 175 people
- Sponsor
- AbbVie
Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
This is an open-label, single-arm, phase I clinical trial with dose escalation designed to investigate the safety, tolerability, and pharmacokinetic properties of Human CD19-CD22 Targeted T Cells Infusion.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell, Diffuse Large B Cell Lymphoma
- Trial name
- BAH241 (NCT06213636)
- Testing
- CD19/CD22-CAR T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech